Amgen Inc. (AMGN)

Name: Amgen Inc. (AMGN): results, filings decoded, planned insider sales, 13F holders, insiders, Congress and short interest
Creator: GreekSoup
License: https://creativecommons.org/licenses/by/4.0/

Compare with another name

Amgen Inc. (AMGN) reported revenue of $10.1 billion for Q2 FY2026, the quarter ended 30 June 2026, up 9.5% on the same quarter a year earlier. Net income was $2.4 billion, up 65.9% on the year, and diluted earnings per share $4.37. The figures are the company's own, from the 10-Q it filed with the SEC on 5 August 2026.

Revenue$10.1 billionup 9.5%

Net income$2.4 billionup 65.9%

Diluted EPS$4.37

QuarterQ2 FY2026ended 30 June 2026

Ratios

From the filings

ROE74.8%

ROCE16.6%

Operating margin30.0%

Net margin23.0%

FCF margin26.7%

Interest cover4.28

Debt to equity4.90

Cash conversion1.43

Share count, 1 year0.4%

Sales CAGR, 3 years11.8%

Profit CAGR, 3 years5.6%

EPS, TTM$16.09

At the close of 21 September 2026

Price$393.16

Market cap$212.5 billion

Stock P/E24.44

Price to book18.18

EV / EBITDA18.11

Dividend yield1.9%

Market cap / sales5.58

52-week high$444.12

52-week low$271.18

Price, 1 year37.8%

Price CAGR, 3 years13.7%

Price CAGR, 5 years13.0%

Every figure is arithmetic on the filed lines (hover a name for the formula); the priced ones use the latest daily close, CBOE delayed quotes, daily history, by CBOE, for splits. Debt to equity here stands on long-term debt as Amgen Inc. files it, with lease liabilities counted separately and never inside it. Nothing here is a valuation or a view.

Price, 17 September 2021 to 21 September 2026

Show

50-day average 200-day average Volume

Daily closes from CBOE delayed quotes, daily history, by CBOE, for splits; the last is 21 September 2026. P/E is the close over the trailing four quarters' EPS as filed at each filing date, on the current share count; the dashed line is the median over the range shown. Sales and margin are quarterly revenue and the operating margin from the tables above. EV/EBITDA, price to book and market cap to sales use the latest filed balance sheet and share count at each date. Drawn in your browser; the range and overlay you pick are remembered here only.

The public record on AMGN

Filings	23 in twelve months: 10 current reports (8-K), about 4 results of operations; 2 officer or director change; 1 material cybersecurity incident; 1 shareholder vote; 1 material agreement
Planned insider sales	10 Form 144 notices in twelve months, $29.3 million; latest 13 August 2026
Options tape	put/call 1.28 by open interest on 23 September 2026; the straddle prices a 2.3% move to 25 September 2026
Holders	10 of the followed funds hold it; largest Geode Capital Management; 3 Schedule 13D or 13G filings in twelve months
Insider trading	7 sales and 0 purchases on Form 4 in twelve months
Congress	4 House trades disclosed in six months
Short interest	13.0 million shares short, 5.62 days to cover at 31 August 2026
Documents	the 10-K, the 10-Qs, the proxy and 4 earnings press releases, each linked

Quarterly results, the last 12 quarters

	Q3 FY2023	Q4 FY2023 *	Q1 FY2024	Q2 FY2024	Q3 FY2024	Q4 FY2024 *	Q1 FY2025	Q2 FY2025	Q3 FY2025	Q4 FY2025 *	Q1 FY2026	Q2 FY2026
Revenue	6,903	8,196	7,447	8,388	8,503	9,086	8,149	9,179	9,557	9,866	8,618	10,054
Cost of revenue	1,806	3,112	3,200	3,236	3,310	3,112	2,968	3,011	3,082	2,976	2,744	2,811
Gross profit	5,097	5,084	4,247	5,152	5,193	5,974	5,181	6,168	6,475	6,890	5,874	7,243
Gross margin	74%	62%	57%	61%	61%	66%	64%	67%	68%	70%	68%	72%
R&D	1,079	1,534	1,343	1,447	1,450	1,724	1,486	1,744	1,900	2,142	1,719	1,868
SG&A	1,353	2,274	1,808	1,785	1,625	1,878	1,687	1,691	1,720	1,952	1,602	1,745
Operating income	2,021	1,271	991	1,909	2,047	2,311	1,178	2,656	2,526	2,720	2,666	3,514
Operating margin	29%	16%	13%	23%	24%	25%	14%	29%	26%	28%	31%	35%
Interest expense	759	821	824	808	776	747	723	694	685	653	657	673
Pre-tax income	1,947	852	-68.0	794	3,101	782	1,973	1,568	3,921	1,514	2,084	2,768
Tax rate	11%	10%	n/a	6%	9%	20%	12%	9%	18%	12%	13%	14%
Net income	1,730	767	-113	746	2,830	627	1,730	1,432	3,216	1,333	1,819	2,375
Net margin	25%	9%	-2%	9%	33%	7%	21%	16%	34%	14%	21%	24%
Diluted EPS	$3.22	$1.42	-$0.21	$1.38	$5.22	$1.17	$3.20	$2.65	$5.93	$2.45	$3.34	$4.37
Operating cash flow	2,760	538	689	2,459	3,571	4,771	1,391	2,280	4,684	1,603	2,189	4,002
Capital expenditure	248	249	230	238	257	371	411	369	436	642	712	513
Free cash flow	2,512	289	459	2,221	3,314	4,400	980	1,911	4,248	961	1,477	3,489
Buybacks	0.0	0.0	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a	n/a
Dividends paid	1,140	1,140	1,208	1,209	1,210	1,205	1,279	1,280	1,282	1,283	1,358	1,362
Shares outstanding	535m	535m	536m	537m	538m	537m	538m	538m	538m	539m	540m	541m
Filing	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q	10-Q	10-K	10-Q	10-Q

* The fourth quarter is the full year less the first three quarters, because the company files the year and not the quarter on its own. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and the share count are as they are. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Cash flow lines filed year to date are the difference between two filings. Shares outstanding are at the period end where the balance sheet tags them, otherwise the count on the filing's cover page. A derived fourth-quarter EPS is left blank when a split in the year makes the arithmetic meaningless.

Profit and loss, 12 fiscal years and the trailing twelve months

	FY2014 †	FY2015 †	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025	TTM
Revenue	20,063	21,662	22,991	22,849	23,747	23,362	25,424	25,979	26,323	28,190	33,424	36,751	38,095
Cost of revenue	4,422	4,227	4,162	4,069	4,101	4,356	6,159	6,454	6,406	8,451	12,858	12,037	11,613
Gross profit	15,641	17,435	18,829	18,780	19,646	19,006	19,265	19,525	19,917	19,739	20,566	24,714	26,482
Gross margin	78.0%	80.5%	81.9%	82.2%	82.7%	81.4%	75.8%	75.2%	75.7%	70.0%	61.5%	67.2%	69.5%
Research and development	4,297	4,070	3,840	3,562	3,737	4,116	4,207	4,819	4,434	4,784	5,964	7,272	7,629
Selling, general and administrative	4,699	4,846	5,062	4,870	5,332	5,150	5,730	5,368	5,414	6,179	7,096	7,050	7,019
Operating income	6,191	8,470	9,794	9,973	10,263	9,674	9,139	7,639	9,566	7,897	7,258	9,080	11,426
Operating margin	30.9%	39.1%	42.6%	43.6%	43.2%	41.4%	35.9%	29.4%	36.3%	28.0%	21.7%	24.7%	30.0%
Interest expense	1,071	1,095	1,260	1,304	1,392	1,289	1,262	1,197	1,406	2,875	3,155	2,755	2,668
Pre-tax income	5,585	7,978	9,163	9,597	9,545	9,138	8,133	6,701	7,346	7,855	4,609	8,976	10,287
Income tax	427	1,039	1,441	7,618	1,151	1,296	869	808	794	1,138	519	1,265	1,544
Effective tax rate	7.6%	13.0%	15.7%	79.4%	12.1%	14.2%	10.7%	12.1%	10.8%	14.5%	11.3%	14.1%	15.0%
Net income	5,158	6,939	7,722	1,979	8,394	7,842	7,264	5,893	6,552	6,717	4,090	7,711	8,743
Net margin	25.7%	32.0%	33.6%	8.7%	35.3%	33.6%	28.6%	22.7%	24.9%	23.8%	12.2%	21.0%	23.0%
Diluted EPS	$6.70	$9.06	$10.24	$2.69	$12.62	$12.88	$12.31	$10.28	$12.11	$12.49	$7.56	$14.23	$16.09
Filing	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K

Income statement lines from each year's 10-K, the year linked to its filing; TTM is the sum of the last four quarters. Free cash flow is operating cash flow less capital expenditure; the effective tax rate is income tax over pre-tax income; margins are the line over revenue. Gross profit is revenue less cost of revenue, and operating income is revenue less the company's own total costs, where the statement does not print those lines. Those four are arithmetic on the filed numbers; everything else is as filed. Money is in $ million as the company files it, or in $ billion by the switch above the tables; per share figures and share counts are as they are. † The year as the company last restated it in a later filing; rest on a figure for the one first filed. EPS is as filed.

Cash flow and capital returned

	FY2014 †	FY2015 †	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025	TTM
Operating cash flow	8,952	9,731	10,354	11,177	11,296	9,150	10,497	9,261	9,721	8,471	11,490	9,958	12,478
Capital expenditure	718	594	738	664	738	618	608	880	936	1,112	1,096	1,858	2,303
Free cash flow	8,234	9,137	9,616	10,513	10,558	8,532	9,889	8,381	8,785	7,359	10,394	8,100	10,175
Free cash flow margin	41.0%	42.2%	41.8%	46.0%	44.5%	36.5%	38.9%	32.3%	33.4%	26.1%	31.1%	22.0%	26.7%
Depreciation and amortisation	2,092	2,108	2,105	1,955	1,946	2,206	3,601	3,398	3,417	4,071	5,592	5,167	2,702
Share-based compensation	408	322	311	329	311	308	330	341	401	431	530	494	492
Buybacks	138	1,867	2,965	3,160	17,794	7,702	3,486	4,975	6,360	0.0	200	0.0	n/a
Dividends paid	1,851	2,396	2,998	3,365	3,507	3,509	3,755	4,013	4,196	4,556	4,832	5,124	5,285
Dividend per share	n/a	n/a	$4.15	$4.77	$5.41	$5.95	$6.56	$7.22	$7.95	$8.64	$9.13	$9.66	$7.28
Diluted shares, weighted	770m	766m	754m	735m	665m	609m	590m	573m	541m	538m	541m	542m	544m
Shares outstanding at period end	760m	754m	738m	722m	630m	591m	578m	558m	534m	535m	537m	539m	541m
Filing	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K

Buybacks and dividends are the cash paid in the year, from the cash flow statement; the dividend per share is as declared. Diluted shares are the weighted average for the year; a falling count is the buybacks net of issuance. TTM sums the last four quarters; the share counts are the latest quarter's.

Balance sheet at year end

	FY2014 †	FY2015 †	FY2016	FY2017	FY2018	FY2019	FY2020	FY2021	FY2022	FY2023	FY2024	FY2025	TTM
Total assets	69,009	71,576	77,626	79,954	66,416	59,707	62,948	61,165	65,121	97,154	91,839	90,586	95,639
Cash and equivalents	3,731	4,144	3,241	3,800	6,945	6,037	6,266	7,989	7,629	10,944	11,973	9,129	13,989
Receivables	2,546	2,995	3,165	3,237	3,580	4,057	4,525	4,895	5,563	7,268	6,782	9,570	10,227
Inventory	2,647	2,435	2,745	2,834	2,940	3,584	3,893	4,086	4,930	9,518	6,998	6,225	6,220
Goodwill	14,788	14,751	14,751	14,761	14,699	14,703	14,689	14,890	15,529	18,629	18,637	18,680	18,668
Long-term debt	30,715	31,429	34,596	35,342	33,929	29,903	32,986	33,309	38,945	64,613	60,099	54,604	57,304
Operating lease liabilities	n/a	n/a	n/a	n/a	n/a	388	306	525	539	691	673	696	n/a
Shareholders' equity	25,778	28,083	29,875	25,241	12,500	9,673	9,409	6,700	3,661	6,232	5,877	8,658	11,688
Filing	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K	10-K

At the fiscal year end; the TTM column is the latest quarter end. A line the company does not tag under the usual name is left out.

Compounded growth

	10 years	5 years	3 years	TTM
Sales growth, compounded	5.4%	7.6%	11.8%	9.1%
Profit growth, compounded	1.1%	1.2%	5.6%	32.1%
Return on equity, average	79.2%	106.7%	88.8%	89.1%

Compounded growth is the latest fiscal year over the year that many years earlier, annualised; the TTM column is the last four quarters over the four before. Return on equity is net income over shareholders' equity at each year end, averaged over the window (the TTM column is the latest year alone); equity is the parent's shareholders' equity as tagged in the 10-K. Arithmetic on filed numbers, nothing forecast.

Peers: Biological Products, (No Diagnostic Substances)

Company	Market cap	P/E	ROE	Op. margin	Sales growth TTM	Debt to equity	Div. yield
Amgen Inc. AMGN	$212.5 billion	24.44	74.8%	30.0%	9.1%	4.90	1.9%
Gilead Sciences, Inc. GILD	$186.8 billion	n/a	-27.4%	-8.2%	5.5%	2.22	2.1%
Moderna, Inc. MRNA	$69.0 billion	n/a	-46.6%	-149.0%	-27.6%	0.09	n/a
Biogen Inc. BIIB	$32.3 billion	23.56	7.4%	16.3%	1.2%	0.34	n/a
Bio-Techne Corp. TECH	$11.3 billion	62.47	8.6%	20.7%	-0.4%	0.09	0.4%

The names on this site in the same industry (the SEC's SIC description), by market capitalisation. Each figure is the same arithmetic as the ratio box above, on each company's own filings and latest close.

Filings

Filing	Period	Filed	Where
10-Q	30 June 2026	5 August 2026	EDGAR
10-Q	31 March 2026	1 May 2026	EDGAR
10-K	31 December 2025	13 February 2026	EDGAR
10-Q	30 September 2025	5 November 2025	EDGAR
10-Q	30 June 2025	6 August 2025	EDGAR
10-Q	31 March 2025	2 May 2025	EDGAR
10-K	31 December 2024	14 February 2025	EDGAR
10-Q	30 September 2024	31 October 2024	EDGAR
10-Q	30 June 2024	7 August 2024	EDGAR
10-Q	31 March 2024	3 May 2024	EDGAR

The same record on your computer

GreekSoup is also a free program for your own computer. It reads these same filings for the names you follow, refreshed as they land, with no account. One pasted line installs it.

Install